News | ACC | March 20, 2018

Statins May Bring Benefits at Time of Treatment for Heart Attack, Angina

Patients undergoing percutaneous coronary intervention fared better when given statins


Statins May Bring Benefits at Time of Treatment for Heart Attack, Angina

Image from presentation, "Statins Evaluation in Coronary Procedures and Revascularization," Berwanger 

March 20, 2018 — Getting a large dose of a statin did not have an impact on major adverse cardiac events among a broad population of patients slated to undergo percutaneous coronary intervention (PCI), a procedure to clear blocked arteries, in a trial being presented at the American College of Cardiology’s 67th Annual Scientific Session. However, statins did significantly reduce the rates of such events among the subset of trial participants who actually underwent PCI.                    

PCI is one of several treatments for people with acute coronary syndrome, an umbrella term that encompasses heart attacks and unstable angina (acute chest pain caused by narrowed arteries). The procedure involves threading a thin wire to the site of the blockage and then inflating a small balloon to open the artery and improve the flow of blood to the heart. In this trial, patients were randomized to receive either a placebo or a “loading dose” of a statin, consisting of two double-doses administered the day before and the day after a scheduled PCI, followed by a daily low-dose of a statin for 30 days.                   

The trial is the largest study to date aimed at testing the hypothesis that statins could help reduce cardiovascular events around the time of PCI. More than 4,100 patients were enrolled in the trial at 58 centers in Brazil. All patients had acute coronary syndrome for which doctors planned to perform PCI within seven days. However, about one-third of the study participants ultimately did not receive PCI because doctors opted to perform other treatments, such as coronary artery bypass grafting (a heart bypass).                    

Participants in this study were reflective of the broader population of people with acute coronary syndrome, and the study protocols were reflective of common hospital practices, said Otavio Berwanger, M.D., Ph.D., cardiologist and clinical epidemiologist at the Brazilian Clinical Research Institute, Sao Paulo, Brazil, and the study’s lead author. He suggested that the results would likely be applicable in many countries and healthcare environments. About 70 percent of the patients had never taken statins and about 30 percent had taken them previously or were on low-dose statins when they enrolled in the study. Patients who were already taking a maximum tolerated dose of statins were excluded.                    

Statins are a widely-used class of drugs that lower LDL, or “bad” cholesterol, thereby helping to prevent serious cardiovascular events in people at high risk for heart disease. In addition to their long-term preventive benefits, basic research suggests statins also may affect processes involved in inflammation and the formation of blood clots.                

In this study, half of the participants were randomly assigned to receive two double (80 milligram) doses of atorvastatin—one shortly before the procedure and one within a day afterward. The other half received two doses of a placebo. Neither patients nor their doctors knew who had received the placebo. All patients then took 40 milligrams of atorvastatin daily for 30 days, which is standard practice after acute coronary syndrome.                    

For 30 days, researchers tracked rates of major adverse cardiac events (the trial’s primary endpoint), which included death, heart attack, stroke or urgent procedures to clear blocked arteries.                    

Among all patients, the primary endpoint occurred in 6.2 percent of those taking the statin and 7.1 percent of those taking the placebo, a difference that was not statistically significant. Among patients who received PCI, the primary endpoint occurred in 6 percent of those taking the statin and 8.2 percent of those taking the placebo, a reduction that was statistically significant.                    

“Although the trial is negative for our primary endpoint in the full study population, the findings of our prespecified analysis are very consistent with smaller trials and observational studies that suggest a reduction in events in the PCI population,” Berwanger said. “Viewed in the context of the literature, our study helps to confirm what has been shown before and suggests that it can be beneficial to consider giving a loading dose of a statin to patients who undergo PCI.”                    

Overall, patients who underwent PCI and received a loading dose of statins were 28 percent less likely to experience a major adverse cardiac event and 32 percent less likely to have a heart attack compared with those taking the placebo.                    

“This study adds another piece to the puzzle,” Berwanger said. “I think it also opens the stage for testing other lipid-lowering agents that may have effects beyond lowering lipids.”                  

Researchers will continue to track outcomes for 12 months. In addition, the team is planning another trial focused on assessing potential benefits of statins and other drugs in patients undergoing PCI.                   

Links to all the ACC 2018 Late-Breaking Trials

For more information:



Related Content

A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle
Drug Stops Dangerous Bleeding in Patients Taking Factor Xa Inhibitors


News | ACC | March 22, 2018
March 22, 2018 — The experimental drug...
Videos | ACC | March 21, 2018
DAIC Editor Dave Fornell takes a tour of some of the most interesting new technologies on the expo floor at
ACC 2018 Late-Breaking Trials Announced
News | ACC | March 21, 2018
Here is a list of the American College of Cardiology (ACC) 2018 annual meeting late-breaking clinical trials presente
Inhaled Therapy Ineffective in Difficult-to-Treat Heart Failure at ACC 2018.

Image from presentation, "Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF: The INDIE-HFpEF Trial," Borlaug

News | ACC | March 20, 2018
March 20, 2018 — Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily a
Trial for Gout Drug Meets Primary Endpoint, Raises Safety Concerns, image shows a CT scan showing gout in the knees.
News | ACC | March 20, 2018
March 20, 2018 — Febuxostat, a gout dr...
More Deaths, Strokes Seen with Perioperative Beta Blocker One Year After Surgery

Image from presentation, "1-Year outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery," Devereaux 

News | ACC | March 20, 2018
March 20, 2018 — During the 12 months after undergoing noncardiac surgery, patients with or at risk for heart disease
Canakinumab Doesn’t Prevent Prediabetes from Progressing to Diabetes according to a late-breaking study at ACC 2018.
News | ACC | March 20, 2018
March 20, 2018 — The anti-inflammatory...
Dabigatran Reduces Major Cardiovascular Complications in Patients With Myocardial Injury after Noncardiac Surgery
News | ACC | March 20, 2018
March 20, 2018 — Treatment with the blood-thinning drug dabigatran significantly reduced the risk of death, heart att
Ticagrelor Has Comparable Safety to Clopidogrel after Heart Attack

Image from presentation, "Ticagrelor Versus Clopidogrel After Thrombolytic Therapy in Patients With St-Elevation Myocardial Infarction: A Randomized Clinical Trial," Berwanger 

News | ACC | March 20, 2018
March 20, 2018 — Among people younger than 75 years who were given clot busters to treat a heart attack, taking the m
Overlay Init